Bank of Montreal
ACRV icon

Bank of Montreal’s Acrivon Therapeutics ACRV Stock Holding History

Bank of Montreal’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-42,444
Closed -$545K – 3760
2022
Q4 		$545K Buy
+42,444
New +$539K ﹤0.01% 2558

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Bank of Montreal's ACRV Position: Q1 2023 in Review

Bank of Montreal sold out of Acrivon Therapeutics (ACRV) in Q1 2023, closing a stake of 42,444 shares — an estimated $545K sold.

Bank of Montreal first reported a position in ACRV in Q4 2022 and held it in 1 quarter. The position peaked at $545K in Q4 2022. 39 funds tracked by Wall St. Rank hold ACRV as of Q1 2023.

  • Bank of Montreal reported no remaining Acrivon Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Bank of Montreal sold 42,444 Acrivon Therapeutics shares in Q1 2023, an estimated $545K.
  • Bank of Montreal first reported a position in Acrivon Therapeutics in Q4 2022 and held it in 1 quarter.
  • Bank of Montreal's Acrivon Therapeutics position peaked at $545K in Q4 2022.
  • 39 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2023.

Based on Bank of Montreal's 13F filing for Q1 2023, filed 13 Jun 2024.